Tad Schoedel, MD
Ophthalmology · Roanoke, VANPI 1083972913
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,864 of the $11,712 with a category attached, or 75.7%. 21 manufacturers reported payments, led by Glaukos Corporation at 34.0% of the total. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $44.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$4K
- Alcon$2K
- AbbVie$2K
- NEW World Medical,inc.$1K
- Bausch & Lomb Americas Inc.$293
- Ocular Therapeutix, Inc.$262
- plus $1K from 15 others
Across 3 payments — averaging $1900.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$3K
- Alcon Research LLC$3K
What the payments were for
- Consulting fees$1501%
- Speaking & faculty fees$2,67923%
- Food & beverage$8,86476%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 28 | $3,981 |
| Alcon | 60 | $2,488 |
| AbbVie(2 entities) | 95 | $2,067 |
| NEW World Medical,inc. | 11 | $1,290 |
| Bausch & Lomb Americas Inc. | 13 | $293 |
| Ocular Therapeutix, Inc. | 10 | $262 |
| Ivantis, Inc | 3 | $234 |
| Novartis | 4 | $213 |
| Aerie Pharmaceuticals, Inc. | 11 | $211 |
| Alimera Sciences, Inc. | 1 | $127 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $105 |
| Harrow Eye, LLC | 3 | $81 |
| Amgen(2 entities) | 5 | $78 |
| Omeros Corporation | 4 | $74 |
| Rayner Intraocular Lenses Limited | 2 | $57 |
| Sight Sciences, Inc. | 2 | $45 |
| Thea Pharma Inc. | 1 | $23 |
| Biotissue Holdings Inc. | 1 | $23 |
| Seagen Inc. | 1 | $22 |
| Eyepoint US, Inc. | 1 | $20 |
| Carl Zeiss Meditec AG | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Trabecular Micro-Bypass System Model iS3$2,500
- Ahmed Glaucoma Valve$873
- Kahook Dual Blade$873
- Streamline Surgical System$509
- XEN GLAUCOMA TREATMENT SYSTEM$357
- iDoseTR$280
- Clareon$253
- LenSx$249
- Hydrus Microstent$234
- DURYSTA$220
- iDose$181
- KXL System$179
- iStent infinite Trabecular Micro-Bypass System Model iS3$179
- Hydrus$150
- SIMBRINZA$141
- Rocklatan$141
- Rhopressa$141
- AcrySof IQ PanOptix UV IOL$141
- NGENUITY$128
- Luxor$128
How this compares
$11,712 in reported general payments places this provider in the 90th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 652 | $231,674 |
| RhopressaNetarsudil Mesylate | 375 | $158,758 |
| RocklatanNetarsudil Mesylat/Latanoprost | 147 | $75,783 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 266 | $71,047 |
| CombiganBrimonidine Tartrate/Timolol | 173 | $54,712 |
| VyzultaLatanoprostene Bunod | 135 | $48,901 |
| Alphagan PBrimonidine Tartrate | 86 | $37,305 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 2,361 | $33,293 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 239 | $29,941 |
| Travoprost | 216 | $28,285 |
| RestasisCyclosporine | 29 | $27,377 |
| Latanoprost | 4,277 | $27,011 |
| Brimonidine Tartrate | 1,542 | $25,171 |
| XiidraLifitegrast | 25 | $25,159 |
| Prednisolone Acetate | 800 | $25,019 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P, Restasis, Restasis Multidose | $2,067 | $360,539955 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $211 | $234,541522 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $293 | $74,060160 claims |
| AlconSimbrinza | $2,488 | $71,047266 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $105 | $5,52020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Roanoke
- Frank CotterRoanoke$15K
- Jonathan TillRoanoke$9K
- William ThompsonRoanoke$9K
- Bryan StrelowRoanoke$7K
- Ethnie JonesRichmond$2M
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Marc OdrichCharlottesville$497K
- Jayakrishna AmbatiCharlottesville$116K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.